Anti-adhesion molecule monoclonal antibodies

Therapeutic potential in ischaemic stroke

Wayne Clark, Justin A. Zivin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Leucocytges appear to potentiate stroke injury by clogging the microcirculation and infiltrating into the brain where they release free radicals and other substances that are toxic to neurons. Through the use of specific monoclonal antibodies directed against leucocyte adhesion receptors, both the microcirculation obstruction and the leucocyte infiltration can be decreased. Experimental studies have found reduced stroke damage through the use of antibodies that bind to either the CD18 leucocyte adhesion receptor or the corresponding endothelial cell receptor, intercellular adhesion molecule-1 (ICAM-1). These studies have shown the most benefit when anti-adhesion monoclonal antibodies are used in experimental models in which reperfusion follows an initial period of ischaemia. Based on these encouraging experimental results, a clinical trial using an anti-ICAM-1 adhesion agent had just been completed, with final results expected soon.

Original languageEnglish (US)
Pages (from-to)90-99
Number of pages10
JournalCNS Drugs
Volume6
Issue number2
StatePublished - 1996

Fingerprint

Leukocyte-Adhesion Receptors
Intercellular Adhesion Molecule-1
Microcirculation
Stroke
Monoclonal Antibodies
Poisons
Reperfusion
Free Radicals
Leukocytes
Theoretical Models
Ischemia
Endothelial Cells
Clinical Trials
Neurons
Antibodies
Wounds and Injuries
Brain
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Neuropsychology and Physiological Psychology

Cite this

Anti-adhesion molecule monoclonal antibodies : Therapeutic potential in ischaemic stroke. / Clark, Wayne; Zivin, Justin A.

In: CNS Drugs, Vol. 6, No. 2, 1996, p. 90-99.

Research output: Contribution to journalArticle

@article{2735093c685d457186e94fb946de2d92,
title = "Anti-adhesion molecule monoclonal antibodies: Therapeutic potential in ischaemic stroke",
abstract = "Leucocytges appear to potentiate stroke injury by clogging the microcirculation and infiltrating into the brain where they release free radicals and other substances that are toxic to neurons. Through the use of specific monoclonal antibodies directed against leucocyte adhesion receptors, both the microcirculation obstruction and the leucocyte infiltration can be decreased. Experimental studies have found reduced stroke damage through the use of antibodies that bind to either the CD18 leucocyte adhesion receptor or the corresponding endothelial cell receptor, intercellular adhesion molecule-1 (ICAM-1). These studies have shown the most benefit when anti-adhesion monoclonal antibodies are used in experimental models in which reperfusion follows an initial period of ischaemia. Based on these encouraging experimental results, a clinical trial using an anti-ICAM-1 adhesion agent had just been completed, with final results expected soon.",
author = "Wayne Clark and Zivin, {Justin A.}",
year = "1996",
language = "English (US)",
volume = "6",
pages = "90--99",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Anti-adhesion molecule monoclonal antibodies

T2 - Therapeutic potential in ischaemic stroke

AU - Clark, Wayne

AU - Zivin, Justin A.

PY - 1996

Y1 - 1996

N2 - Leucocytges appear to potentiate stroke injury by clogging the microcirculation and infiltrating into the brain where they release free radicals and other substances that are toxic to neurons. Through the use of specific monoclonal antibodies directed against leucocyte adhesion receptors, both the microcirculation obstruction and the leucocyte infiltration can be decreased. Experimental studies have found reduced stroke damage through the use of antibodies that bind to either the CD18 leucocyte adhesion receptor or the corresponding endothelial cell receptor, intercellular adhesion molecule-1 (ICAM-1). These studies have shown the most benefit when anti-adhesion monoclonal antibodies are used in experimental models in which reperfusion follows an initial period of ischaemia. Based on these encouraging experimental results, a clinical trial using an anti-ICAM-1 adhesion agent had just been completed, with final results expected soon.

AB - Leucocytges appear to potentiate stroke injury by clogging the microcirculation and infiltrating into the brain where they release free radicals and other substances that are toxic to neurons. Through the use of specific monoclonal antibodies directed against leucocyte adhesion receptors, both the microcirculation obstruction and the leucocyte infiltration can be decreased. Experimental studies have found reduced stroke damage through the use of antibodies that bind to either the CD18 leucocyte adhesion receptor or the corresponding endothelial cell receptor, intercellular adhesion molecule-1 (ICAM-1). These studies have shown the most benefit when anti-adhesion monoclonal antibodies are used in experimental models in which reperfusion follows an initial period of ischaemia. Based on these encouraging experimental results, a clinical trial using an anti-ICAM-1 adhesion agent had just been completed, with final results expected soon.

UR - http://www.scopus.com/inward/record.url?scp=0029742656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029742656&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 90

EP - 99

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 2

ER -